| The Prognostic and Immune Significance of BZW2 in Pan-Cancer and its Relationship with Proliferation and Apoptosis of Cervical Cancer. | The Prognostic and Immune Significance of BZW2 in Pan-Cancer and its Relationship with Proliferation and Apoptosis of Cervical Cancer.
Li C, Li Q, Li L, Sun S, Lei X. | 04/3/2024 |
| Interactome Analysis Identifies the Role of BZW2 in Promoting Endoplasmic Reticulum-Mitochondria Contact and Mitochondrial Metabolism. | Interactome Analysis Identifies the Role of BZW2 in Promoting Endoplasmic Reticulum-Mitochondria Contact and Mitochondrial Metabolism.
Maio G, Smith M, Bhawal R, Zhang S, Baskin JM, Li J, Lin H., Free PMC Article | 02/26/2024 |
| BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis. | BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis.
Agarwal S, Afaq F, Bajpai P, Behring M, Kim HG, Varambally A, Chandrashekar DS, Peter S, Diffalha SA, Khushman M, Seeber A, Varambally S, Manne U., Free PMC Article | 07/7/2023 |
| m6A methyltransferase METTL3 facilitates multiple myeloma cell growth through the m6A modification of BZW2. | m6A methyltransferase METTL3 facilitates multiple myeloma cell growth through the m6A modification of BZW2.
Huang X, Yang Z, Li Y, Long X. | 06/22/2023 |
| miR-140-3p attenuated the tumorigenesis of multiple myeloma via attenuating BZW2. | miR-140-3p attenuated the tumorigenesis of multiple myeloma via attenuating BZW2.
Long X, Li J, Wen F, Cao Y, Luo Z, Luo C. | 02/19/2022 |
| Human oncoprotein 5MP suppresses general and repeat-associated non-AUG translation via eIF3 by a common mechanism. | Human oncoprotein 5MP suppresses general and repeat-associated non-AUG translation via eIF3 by a common mechanism.
Singh CR, Glineburg MR, Moore C, Tani N, Jaiswal R, Zou Y, Aube E, Gillaspie S, Thornton M, Cecil A, Hilgers M, Takasu A, Asano I, Asano M, Escalante CR, Nakamura A, Todd PK, Asano K., Free PMC Article | 02/12/2022 |
| BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway. | BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway.
Huang L, Chen S, Fan H, Ai F, Sheng W. | 03/13/2021 |
| BZW2 has an oncogenic role in muscle-invasive bladder cancer and serves as a promising target for molecular diagnosis and gene therapy. | BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: A microarray pathway analysis.
Gao H, Yu G, Zhang X, Yu S, Sun Y, Li Y., Free PMC Article | 08/1/2020 |
| 5MP1 is a novel oncogene that reprograms c-Myc translation in CRC. 5MP1 could be a potential therapeutic target to overcome therapeutic resistance conferred by tumor heterogeneity of CRC. | Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer.
Sato K, Masuda T, Hu Q, Tobo T, Gillaspie S, Niida A, Thornton M, Kuroda Y, Eguchi H, Nakagawa T, Asano K, Mimori K., Free PMC Article | 12/14/2019 |
| These data demonstrated that the knockdown of BZW2 suppresses protein phosphorylation in the Akt/mTOR signaling pathway. These observations suggest that BZW2 is upregulated and has a pro-tumor effect in osteosarcoma via activation of the Akt/mTOR signaling pathway and thus is a potential target for gene therapy. | Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.
Cheng DD, Li SJ, Zhu B, Yuan T, Yang QC, Fan CY., Free PMC Article | 05/12/2018 |
| results reveal a surprising role for BZW1 and BZW2 in maintaining homeostatic stringency of start codon selection, and taking into account recent biochemical, genetic and structural insights into eukaryotic initiation, suggest a model for BZW1 and BZW2 function | Translational autoregulation of BZW1 and BZW2 expression by modulating the stringency of start codon selection.
Loughran G, Firth AE, Atkins JF, Ivanov IP., Free PMC Article | 04/7/2018 |
| Data show that eIF5-mimic protein (5MP) represses non-AUG translation by competing with translation initiation factor 5 (eIF5) for the Met-tRNAi-binding factor eIF2. | Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide.
Tang L, Morris J, Wan J, Moore C, Fujita Y, Gillaspie S, Aube E, Nanda J, Marques M, Jangal M, Anderson A, Cox C, Hiraishi H, Dong L, Saito H, Singh CR, Witcher M, Topisirovic I, Qian SB, Asano K., Free PMC Article | 12/16/2017 |
| overexpression of eIF5 and 5MP induces translation of ATF4 | Overexpression of eIF5 or its protein mimic 5MP perturbs eIF2 function and induces ATF4 translation through delayed re-initiation.
Kozel C, Thompson B, Hustak S, Moore C, Nakashima A, Singh CR, Reid M, Cox C, Papadopoulos E, Luna RE, Anderson A, Tagami H, Hiraishi H, Slone EA, Yoshino KI, Asano M, Gillaspie S, Nietfeld J, Perchellet JP, Rothenburg S, Masai H, Wagner G, Beeser A, Kikkawa U, Fleming SD, Asano K., Free PMC Article | 06/10/2017 |
| 5MP1 (BZW2) acts as a partial mimic and competitor of eIF5, interfering with the key steps by which eIF5 regulates eIF2 function. | Mechanisms of translational regulation by a human eIF5-mimic protein.
Singh CR, Watanabe R, Zhou D, Jennings MD, Fukao A, Lee B, Ikeda Y, Chiorini JA, Campbell SG, Ashe MP, Fujiwara T, Wek RC, Pavitt GD, Asano K., Free PMC Article | 01/7/2012 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium., Free PMC Article | 09/15/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |